Literature DB >> 30878490

Is lymph node dissection necessary for resectable intrahepatic cholangiocarcinoma? A systematic review and meta-analysis.

Rui Zhou1, Dihan Lu2, Wenda Li1, Wenliang Tan1, Sicong Zhu1, Xianqing Chen1, Jun Min3, Changzhen Shang4, Yajin Chen5.   

Abstract

BACKGROUND: The objective of this meta-analysis was to evaluate the effectiveness and safety of lymph node dissection (LND) in patients with intrahepatic cholangiocarcinoma (ICC).
METHODS: A literature search with a date range of January 2000 to January 2018 was performed to identify studies comparing lymph node dissection (LND+) with non-lymph node dissection (LND-) for patients with ICC. The LND + group was further divided into positive (LND + N+) and negative (LND + N-) lymph node status groups based on pathological analysis.
RESULTS: 13 studies including 1377 patients were eligible. There were no significant differences in overall survival (OS) (HR 1.13, 95% CI 0.94-1.36; P = 0.20), disease-free survival (DFS) (HR 1.23, 95% CI 0.94-1.60; P = 0.13), or recurrence (OR 1.39, 95% CI 0.90-2.15; P = 0.14) between LND + group and LND-group. Postoperative morbidity was significantly higher in the LND + group (OR 2.67, 95% CI 1.74-4.10; P < 0.001). A subset analysis showed that OS was similar between LND + N- and LND-groups (HR 1.13, 95% CI 0.82-1.56; P = 0.450). However when comparing, OS of the LND-group to the LND+N+ group there was a significant increase in OS for the LND-group (HR 3.26, 95% CI 1.85-5.76; P < 0.001).
CONCLUSIONS: LND does not seem to positively affect overall survival and is associated with increased post-operative morbidity.
Copyright © 2019 International Hepato-Pancreato-Biliary Association Inc. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2019        PMID: 30878490     DOI: 10.1016/j.hpb.2018.12.011

Source DB:  PubMed          Journal:  HPB (Oxford)        ISSN: 1365-182X            Impact factor:   3.647


  15 in total

1.  Prognostic factors for patients with mass-forming intrahepatic cholangiocarcinoma: A case series of 68 patients.

Authors:  Jian Feng; Bin Liang; Hang-Yu Zhang; Zhe Liu; Kai Jiang; Xiang-Qian Zhao
Journal:  World J Gastrointest Surg       Date:  2022-05-27

2.  The influence of 18F-fluorodeoxyglucose positron emission tomography/computed tomography on the N- and M-staging and subsequent clinical management of intrahepatic cholangiocarcinoma.

Authors:  Youpei Lin; Huanhuan Chong; Guohe Song; Chenhao Zhang; Liangqing Dong; Ling Aye; Fei Liang; Shuaixi Yang; Mengsu Zeng; Guangyu Ding; Shu Zhang; Jieyi Shi; Aiwu Ke; Xiaoying Wang; Jian Zhou; Jia Fan; Qiang Gao
Journal:  Hepatobiliary Surg Nutr       Date:  2022-10       Impact factor: 8.265

3.  Prognostic Value of Lymph Node Dissection for Intrahepatic Cholangiocarcinoma Patients With Clinically Negative Lymph Node Metastasis: A Multi-Center Study From China.

Authors:  Qiao Ke; Lei Wang; Ziguo Lin; Jianying Lou; Shuguo Zheng; Xinyu Bi; Jianming Wang; Wei Guo; Fuyu Li; Jian Wang; Yamin Zheng; Jingdong Li; Shi Cheng; Weiping Zhou; Yongyi Zeng
Journal:  Front Oncol       Date:  2021-03-11       Impact factor: 6.244

4.  Cholangiocarcinoma: three different entities based on location.

Authors:  Christopher T Aquina; Timothy M Pawlik; Aslam Ejaz
Journal:  Ann Transl Med       Date:  2020-06

5.  Postoperative adjuvant therapy following radical resection for intrahepatic cholangiocarcinoma: A multicenter retrospective study.

Authors:  Lei Wang; Manjun Deng; Qiao Ke; Jianying Lou; Shuguo Zheng; Xinyu Bi; Jianming Wang; Wei Guo; Fuyu Li; Jian Wang; Yamin Zheng; Jingdong Li; Shi Cheng; Weiping Zhou; Yongyi Zeng
Journal:  Cancer Med       Date:  2020-02-19       Impact factor: 4.452

6.  Minimally invasive surgical treatment of intrahepatic cholangiocarcinoma: A systematic review.

Authors:  Renato Patrone; Francesco Izzo; Raffaele Palaia; Vincenza Granata; Guglielmo Nasti; Alessandro Ottaiano; Gilda Pasta; Andrea Belli
Journal:  World J Gastrointest Oncol       Date:  2021-12-15

7.  Evaluation of nodal status in intrahepatic cholangiocarcinoma: a population-based study.

Authors:  Xiaoyuan Chen; Dawei Rong; Long Zhang; Chuangye Ni; Guoyong Han; Yiwei Lu; Xuejiao Chen; Yun Gao; Xuehao Wang
Journal:  Ann Transl Med       Date:  2021-09

8.  Conversion Therapy of Intrahepatic Cholangiocarcinoma Is Associated with Improved Prognosis and Verified by a Case of Patient-Derived Organoid.

Authors:  Zhiwei Wang; Yun Jin; Yinghao Guo; Zhenhua Tan; Xiaoxiao Zhang; Dan Ye; Yuanquan Yu; Shuyou Peng; Lei Zheng; Jiangtao Li
Journal:  Cancers (Basel)       Date:  2021-03-09       Impact factor: 6.639

9.  Development and Validation a Nomogram for Predicting Overall Survival in Patients With Intrahepatic Cholangiocarcinoma.

Authors:  Chen Yuan; Zhigang Hu; Kai Wang; Shubing Zou
Journal:  Front Surg       Date:  2021-05-17

Review 10.  Treatment of Intrahepatic Cholangiocarcinoma-A Multidisciplinary Approach.

Authors:  Felix Krenzien; Nora Nevermann; Alina Krombholz; Christian Benzing; Philipp Haber; Uli Fehrenbach; Georg Lurje; Uwe Pelzer; Johann Pratschke; Moritz Schmelzle; Wenzel Schöning
Journal:  Cancers (Basel)       Date:  2022-01-12       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.